Lymphoma

Lymphomas arise from lymphocytes, cells of the immune system. They can develop in lymph nodes or in sites such as stomach, skin, brain, bone or spleen. A lymphoma in an organ is not automatically treated like a cancer arising from that organ's usual epithelial cells.

The broad division is Hodgkin versus non-Hodgkin lymphoma, followed by precise entities defined by cell lineage, tissue appearance, immune markers and selected genetics. Terms may differ between classification editions. Ask for the complete integrated diagnosis rather than relying on “lymphoma,” “high-grade” or a single positive marker.

Painless enlarging nodes, unexplained fever, drenching night sweats, weight loss, itching or persistent fatigue can occur, but none is specific to lymphoma. Infection and inflammatory conditions may produce similar findings. A normal routine blood count does not rule out a tissue-based lymphoma.

New breathing difficulty, face or neck swelling, neurological weakness, severe abdominal symptoms or rapidly enlarging masses need prompt local assessment. Aggressive lymphomas can grow quickly, and treatment may require urgent tumor-lysis prevention. Do not delay emergency care while collecting documents for a distant review.

An excisional or substantial core biopsy is often needed because tissue architecture and a panel of markers determine the subtype. Fine-needle sampling alone may not provide enough information for a new diagnosis. The safest useful method depends on location and urgency; a difficult-to-reach mass may need an image-guided approach.

Pathology review may require original slides, paraffin blocks, flow cytometry and FISH or other molecular tests. A report pending a decisive marker is not necessarily a mistake. Before non-emergency steroids are started, ask whether they could interfere with the planned biopsy; urgent stabilization remains the priority when organs are threatened.

Start with the exact pathology name. These links lead to different decision pathways, not interchangeable versions of one treatment.

Other specific routes include Burkitt lymphoma, CLL/SLL and Waldenström macroglobulinemia. Primary CNS lymphoma also differs substantially from a systemic lymphoma with secondary CNS involvement. If the diagnosis does not fit a listed page, use a specialist review rather than forcing it into a neighboring category.

Staging describes where disease is found. PET/CT is useful in FDG-avid lymphomas, while CT and other tests may be preferable for particular entities. Bone marrow biopsy is selective: it is not required routinely in every PET-staged Hodgkin or large B-cell lymphoma, but remains useful in other settings.

Stage and aggressiveness are different. Some rapidly growing lymphomas remain potentially curable even when widespread; some slow-growing diseases are managed over many years. Tumor bulk, organ function, symptoms and subtype-specific risk scores add information. Ask whether treatment aims for cure, long-term control or relief of a specific problem.

Selected low-burden indolent lymphomas can be observed, or treated locally if limited. Other lymphomas need prompt systemic treatment. Options include antibodies, chemotherapy, radiotherapy, targeted medicines, antibody–drug conjugates, bispecific antibodies and cellular therapies, but no single list applies to every subtype.

A B-cell antigen such as CD20 or CD19 is relevant only in the appropriate disease setting. PD-1 treatment in classical Hodgkin lymphoma, anti-CD20 therapy in many B-cell lymphomas and asparaginase-based strategies in NK/T disease are different approaches. Confirm the target and evidence rather than choosing solely by the word “immunotherapy.”

PET response uses a structured scale interpreted at a defined treatment time point. Inflammation or infection can cause uptake, and a residual mass can be scar tissue. An equivocal result may need review, repeat imaging or biopsy before a major change; the right action depends on the subtype and protocol.

At suspected relapse, a new biopsy may identify a changed subtype or transformation from indolent to aggressive disease. Timing of relapse and prior response determine whether salvage treatment, autologous transplantation, CAR-T or other options are relevant. ctDNA is promising, but it does not universally replace standard tissue and imaging assessment.

Pre-treatment planning may include heart assessment, hepatitis and HIV testing, fertility preservation, vaccination review and infection prevention. Discuss these early without delaying urgent therapy. Long-term care also considers fatigue, nerve symptoms, heart/lung exposure and later cancer risk according to the treatment received.

Bring the complete pathology with slides/blocks, PET/CT images and reports, blood results, dated regimens, response scans and serious toxicity records. If a biopsy was small or the course does not fit the diagnosis, ask whether expert hematopathology review could change the plan. A usable review should end with a diagnosis, treatment goal and next decision.